Supernus Pharmaceuticals (NASDAQ:SUPN) Rating Lowered to Hold at Zacks Investment Research

Share on StockTwits

Zacks Investment Research lowered shares of Supernus Pharmaceuticals (NASDAQ:SUPN) from a buy rating to a hold rating in a report issued on Wednesday, Zacks.com reports.

According to Zacks, “Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland. “

SUPN has been the subject of several other reports. BidaskClub downgraded shares of Walgreens Boots Alliance from a sell rating to a strong sell rating in a research note on Monday, June 24th. Cantor Fitzgerald reiterated a buy rating and set a $107.00 price objective on shares of Perrigo in a research note on Wednesday, May 8th. Finally, Mizuho reiterated a buy rating on shares of Supernus Pharmaceuticals in a research note on Friday, May 17th. Two analysts have rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company. Supernus Pharmaceuticals has an average rating of Hold and a consensus price target of $55.57.

Shares of SUPN stock opened at $32.02 on Wednesday. Supernus Pharmaceuticals has a one year low of $29.60 and a one year high of $56.40. The company has a quick ratio of 2.59, a current ratio of 2.77 and a debt-to-equity ratio of 0.75. The stock’s 50 day moving average is $31.56. The firm has a market capitalization of $1.69 billion, a price-to-earnings ratio of 15.62, a price-to-earnings-growth ratio of 1.09 and a beta of 1.61.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings results on Tuesday, May 7th. The specialty pharmaceutical company reported $0.34 EPS for the quarter, missing the consensus estimate of $0.44 by ($0.10). Supernus Pharmaceuticals had a return on equity of 23.60% and a net margin of 25.49%. The company had revenue of $85.50 million for the quarter, compared to analyst estimates of $102.26 million. During the same period last year, the company posted $0.49 EPS. The business’s revenue for the quarter was down 5.4% on a year-over-year basis. Sell-side analysts anticipate that Supernus Pharmaceuticals will post 2.25 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Menta Capital LLC boosted its stake in shares of Supernus Pharmaceuticals by 3.5% in the fourth quarter. Menta Capital LLC now owns 7,824 shares of the specialty pharmaceutical company’s stock valued at $260,000 after purchasing an additional 265 shares during the period. Advisor Group Inc. boosted its stake in shares of Supernus Pharmaceuticals by 17.2% in the fourth quarter. Advisor Group Inc. now owns 2,082 shares of the specialty pharmaceutical company’s stock valued at $69,000 after purchasing an additional 306 shares during the period. Oregon Public Employees Retirement Fund boosted its stake in shares of Supernus Pharmaceuticals by 1.8% in the first quarter. Oregon Public Employees Retirement Fund now owns 20,239 shares of the specialty pharmaceutical company’s stock valued at $709,000 after purchasing an additional 366 shares during the period. Campbell Newman Asset Management Inc. boosted its stake in shares of Supernus Pharmaceuticals by 2.5% in the first quarter. Campbell Newman Asset Management Inc. now owns 16,567 shares of the specialty pharmaceutical company’s stock valued at $581,000 after purchasing an additional 397 shares during the period. Finally, Diversified Trust Co boosted its stake in shares of Supernus Pharmaceuticals by 8.4% in the second quarter. Diversified Trust Co now owns 6,450 shares of the specialty pharmaceutical company’s stock valued at $213,000 after purchasing an additional 500 shares during the period. Institutional investors own 99.29% of the company’s stock.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy and migraine.

Featured Story: What are the FAANG Stocks?

Get a free copy of the Zacks research report on Supernus Pharmaceuticals (SUPN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.